Literature DB >> 34988708

Combination of waveforms in modern spinal cord stimulation.

Piedade G S1, Gillner S2, Slotty P J2, Vesper J2.   

Abstract

BACKGROUND: After the surge of burst stimulation, different waveforms were developed to optimize results in spinal cord stimulation. Studies have shown higher responder rates for multiwave therapy, but since the launch of such multiwave systems, little is known about the patients' preference regarding waveforms in the long-term follow-up. No study connected particular waveforms to specific pain etiologies or required stimulation parameters so far.
METHOD: Thirty-four patients with refractory chronic neuropathic pain were treated with spinal cord stimulation systems providing multiwave therapy between September 2018 and October 2019. Patients with a follow-up of at least 6 months were selected; 10 subjects were excluded due to revision surgery, infection, and loss to follow-up. Data regarding pain intensity and preferred waveform for the trial, the implantation, 3-month and 6-month follow-up were recorded.
RESULTS: During the trial phase, 10 patients (43.5%) achieved significant pain relief using tonic stimulation, 5 using burst (21.7%), 3 using microburst (13.0%), and 4 using a combination of tonic and microburst (17.4%). One single patient preferred Contour stimulation during the trial. After 3 months, 6 patients preferred microburst (25%), 6 preferred tonic (25%), 5 used a combination of tonic and microburst (20.8%), and 5 patients used burst (20.8%). After 6 months, similar results were obtained. Contour and Whisper were used in complex cases failing to other waveforms.
CONCLUSIONS: Tonic stimulation, isolated or in combination, remains an important component in spinal cord stimulation, being used by almost half of the patients. Over time, the usage of microburst increased considerably. Whisper and Contour, although battery-consuming, are good salvage options in complex cases.
© 2022. The Author(s).

Entities:  

Keywords:  Combination therapy; Neuropathic pain; Spinal cord stimulation; Waveform

Mesh:

Year:  2022        PMID: 34988708      PMCID: PMC8967740          DOI: 10.1007/s00701-021-05107-4

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


Introduction

The field of spinal cord stimulation (SCS) developed in recent years with new waveforms targeting different needs in the therapy of neuropathic pain. Tonic stimulation (10–150 Hz) was the very first to be developed and provides mostly paresthesia in the stimulated area, which is very useful when evaluating the coverage of the painful area during the first programming session. Burst stimulation was later developed and its first form consisted of five stimulus bursts, classically with an intraburst frequency of 500 Hz, delivered with a frequency of 40 Hz under constant amplitude [3]. It provided significant pain relief to patients previously using classic tonic stimulation [2]. After the surge of burst stimulation that made a paresthesia-free stimulation possible, alternatives such as microburst, Whisper, and Contour appeared and gained relevance in the neuromodulation of the spinal cord (Table 1) [1]. Commercially available systems were developed to provide multiwave therapy—some of them even simultaneously [6]. Systems that allow patients to choose among multiple waveforms were reported to have high responder rates even in previously implanted patients that failed to trials with high-dose SCS [4]. Since the launch of such multiwave systems, little is known about the patients’ preference regarding waveforms in the long-term follow-up. We aim to report our experience with the programming of spinal cord stimulators in the context of multiwave therapy, identify the prevalence of different waveforms over time, and critically discuss the importance of each of them in the treatment of chronic pain.
Table 1

Waveforms provided by the tested devices

Definition
TonicRegular stimuli generally applied with a frequency of 10 to 150 Hz, amplitude up to 25 Hz
BurstIntermittent packets of burst stimuli with 2–7 pulses per packet, interburst frequency of 40 Hz and pulse widths up to 1000 μs, amplitude at 60% of the perception threshold
MicroburstCustomized stimulation with 2–1000 pulses per packet, 1–80 Hz interburst frequency, and up to 1200 Hz intraburst frequency
ContourAlgorithm that shapes the stimulation field over multiple vertebral levels to the spinal anatomy and lead position
WhisperHigh-frequency tonic stimulation between 1000 and 1200 Hz, amplitude at 60% of the perception threshold
Waveforms provided by the tested devices

Methods and materials

Patients with chronic neuropathic pain that were treated with spinal cord stimulation systems providing multiwave therapy between September 2018 and October 2019 in our center were preselected; those achieving at least 6 months of follow-up were included in the study. Data regarding pain intensity and waveform in use for the trial, the implantation, and the follow-up appointments were collected. Pain intensity was assessed with the visual analog scale (VAS). Implanted systems were Spectra Wavewriter™ and Precision Montage™, both manufactured by Boston Scientific Corporation (Marlborough, MA, USA). The first system was used in 13 patients and is the only one to allow simultaneous treatment with two different waveforms using different electrodes. In both systems, the percentage of electric current running through each individual electrode can be controlled. This study was approved by the local IRB (2020–905). We used descriptive statistics in this study.

Results

A total of 34 patients were treated with a spinal cord stimulation system providing multiwave therapy; 10 subjects however did not achieve 6 months of follow-up due to revision surgery, infection, and loss to follow-up and were therefore excluded from the analysis. We analyzed a study pool of 24 patients. Twenty-three patients were submitted to a trial of spinal cord stimulation; in one case, an older IPG was substituted by a device with multiwave therapy. A trial with temporary lead in an out-patient setting was done in 14 patients; in these cases, the trial lasted for 14 days. The remaining 9 patients were submitted to a trial with permanent lead; the trial phase lasted for a maximum of 14 days but could be interrupted earlier for implantation of the IPG. Test of each waveform during the trial lasted for approximately 4 days each. Patients under multiwave therapy had a mean age of 61.8 years at the implantation of the pulse generator (IPG) and were predominantly female (66.7%); mean follow-up of 6.8 months was seen (Table 2). The time period between trial and implant was on average 19.3 days. Failed back surgery syndrome responded for 15 of the indications for spinal cord stimulation (62.5%); mean pain intensity at the baseline was 8.1. A successful trial stimulation was obtained in 10 patients with tonic stimulation (43.5%), followed by burst (5, 21.7%), tonic and microburst (4, 17.3%), microburst (3, 13.0%), and Contour (1, 4.3%). Patient 13 was already under SCS with another system; in a revision surgery, the system was changed without a previous trial using multiwave therapy. After implantation of the IPG, patients were discharged with similar stimulation parameters. Tonic stimulation was rejected by three patients and a good response was seen in 7 cases (29.2%); microburst was chosen by two more individuals and was chosen by 5 discharged patients (20.1%). One single patient was discharged alternating frequently between tonic and burst; the IPG in this case could not provide simultaneous stimulation with both waveforms.
Table 2

Pain intensity and preferred waveform over time

AgeSexPain etiologyLead levelBaselineImplantation Waveform3 months f/u6 months f/u12 months f/u
VASWaveformVASWaveformVASWaveformVASWaveform
151FLow back painT97TonicTonic3MB0Tonic/MB
252MFBSST9 and T79Tonic/MBTonic/MB7Tonic/MB3Tonic/MB2Tonic/MB
371MPost-myelitisC58Tonic/MBTonic/MB5Tonic/MB3Whisper
458MFBSST98MBMB3MB3Tonic/MB
581FFBSST88MBMB8Tonic/MB4Contour
678FFBSST98ContourContour8MB8MB
777FSciaticaT98Tonic/MBMB2MB4MB
884FSciaticaT99TonicTonic5Tonic4Tonic
970FFBSST88BurstTonic/MB4Tonic/MB8Tonic/MB
1067FFBSST88TonicMB1MB1Tonic/MB
1170FFBSST79MBMB3Burst/MB5Burst/MB
1271FFBSST89Tonic/MBTonic/MB2Tonic/MB2MB
1380FFBSST98-MB9MB8MB
1459MSciaticaT97TonicTonic3Tonic7Tonic
1548FSciaticaT96BurstBurst4Burst6Burst5Burst
1658MFBSST88TonicTonic2Tonic4Burst
1747MPeripheral neuropathyT109BurstBurst3Tonic3Tonic
1851MPost-traumaticT89BurstBurst2Burst2Burst
1939FFBSST89TonicBurst0Burst7Tonic/burst
2061FFBSST78TonicTonic3Tonic3Burst
2141FFBSSC46TonicTonic/burst4Tonic/burst2Tonic
2257MFBSST88TonicTonic4Tonic0Tonic
2359FFBSSC57TonicTonic6Burst4Whisper
2453FSciaticaT810BurstBurst3Burst3Burst6Burst

Patients 1–13 were implanted with Spectra WaveWriter™ and could choose two different waveforms to act simultaneously; patients 14–24 were implanted with Precision Montage™. Lead level indicates the vertebral level of the tip of the lead. Subjects are presented in aleatory order. FBSS failed back surgery syndrome, MB microburst

Pain intensity and preferred waveform over time Patients 1–13 were implanted with Spectra WaveWriter™ and could choose two different waveforms to act simultaneously; patients 14–24 were implanted with Precision Montage™. Lead level indicates the vertebral level of the tip of the lead. Subjects are presented in aleatory order. FBSS failed back surgery syndrome, MB microburst After 3 months of follow-up, mean VAS decreased to 3.9, a mean reduction of 51.9% in pain intensity. Overall, 15 patients (62.5%) had a significant pain relief of at least 50%. Tonic and microburst were the most used waveforms, each preferred by 6 patients (25%). Burst and the combination of tonic and microburst were used by 5 patients each (20.8%); the combinations of tonic and burst and of burst and microburst were the case of one patient each (4.2%). At 6 months follow-up, mean VAS stabilized at 3.9 and 16 patients (66.7%) achieved pain relief of at least 50%. Tonic stimulation, burst, and the combination of tonic and microburst were preferred by 5 patients each (20.8%) and were followed by microburst alone (4, 16.7%). Whisper was used by 2 patients (8.3%); Contour and the combinations of burst with microburst and of burst with tonic were preferred by one patient each (4.2%). Table 3 gives a better overview of the prevalence of different waveforms over time. Isolated tonic stimulation was the most frequent waveform in successful trials, but lost half of its patients for other waveforms. Burst and microburst kept roughly a fifth of the patients during the entire duration of the observation period. When combinations are also considered, however, tonic stimulation was an important component of the therapy in 14 patients (60.8%) and at 6 months follow-up still was used by 11 (45.8%), being the most used waveform in this study. Microburst initially was used by 7 individuals (30.3%), progressed to 12 at 3 months follow-up (50%) and at the end responded for 10 study subjects (41.7%). Burst was rarely used in combination with other waveforms; its prevalence grew up from 5 (21.7%) to 7 subjects (29.2%) at 6 months follow-up.
Table 3

Prevalence of waveforms over time

TrialImplantation3 months f/u6 months f/u
Tonic43.5%29.2%25.0%20.8%
Burst21.7%20.8%20.8%20.8%
Microburst13.0%20.1%25.0%16.7%
Contour4.3%4.2%0%4.2%
Whisper0%0%0%8.3%
Tonic + microburst17.3%16.7%20.8%20.8%
Tonic + burst0%4.2%4.2%4.2%
Burst + microburst0%0%4.2%4.2%
Prevalence of waveforms over time

Discussion

This study observed the phenomenon of a decrease in the prevalence of tonic stimulation alone over time, favoring burst, microburst, or a combination. Many patients sense stimulation-induced paresthesia of tonic stimulation as a comfortable feeling. If there is a good coverage and patients do not need higher current intensities, many patients remain using exclusively tonic. In the case, however, that sufficient pain relief can only be achieved using higher current intensities; subperception therapies are generally preferred, such as burst stimulation and microburst. Both waveforms allow a higher tissue activation without the side effects of tonic stimulation using high amplitudes. The same occurs in the case of insufficient coverage of the painful area, when higher amplitudes try to compensate the pain of the uncovered region. That is possibly the reason why combinations between tonic and burst or microburst are frequent during the initial programming and get even more frequent over time. When considered together, burst stimulation and microburst were used by 12 patients during the trial (52%) and after 6 months were a component of the therapy in 17 of them (70.9%). An alternative to burst that reduces battery consumption is microburst, with an intraburst frequency of 450 Hz. Microdosing burst stimulation with alternation of ON and OFF periods was also a successful strategy [10]. In this study, two patients with cervical leads used Whisper stimulation at a frequency of 1 kHz after tonic and burst stimulation failed to provide sufficient pain relief. One subject achieved significant pain relief; the other one had a reduction of 42.8% in pain intensity. High-frequency spinal cord stimulation was initially tested for 10 kHz with superiority to conventional tonic stimulation in the SENZA trial [5]. Equivalent pain relief, however, was obtained using 1 kHz in the PROCO trial, which reduced battery consumption [9]. The Whisper trial tested frequencies up to 1.2 kHz in previously implanted patients and, when the patients were given the choice, increased pain relief was achieved [7]. High-frequency stimulation has been used particularly in the case of cervical leads with good outcomes [8]. Contour was preferred by only two patients in the study at different times. It is a waveform that shapes the stimulation field to the patients’ anatomy, activating uniformly the dorsal columns despite variabilities in the lead position. Contour is now programmed with 200 Hz and its efficacy has been particularly tested with leads with 1 mm edge-to-edge spacing between electrodes. It is however possible to program it with leads with higher spacing. Contour is a good option in minor lead migration. This study has the weakness of being retrospective, even considering the high quality of each case’s documentation. If paresthesia coverage and stimulation parameters had been prospectively assessed, more conclusions could have been drawn about the reasons for the use of a specific waveform in each case. This study has however the strength of depicting the preference for waveforms or a combination of them with a high external validity and provides valuable information for the management of stimulation parameters in the context of multiwave therapy in the mid and long term.

Conclusion

Tonic stimulation, isolated or in combination with other waveforms, is still a very important component of modern SCS. Burst stimulation and microburst represent effective paresthesia-free alternatives. Whisper and Contour, although battery-consuming, are good salvage options in complex cases.
  10 in total

1.  High-frequency spinal cord stimulation at 10 kHz for widespread pain: a retrospective survey of outcomes from combined cervical and thoracic electrode placements.

Authors:  John Salmon
Journal:  Postgrad Med       Date:  2019-04-01       Impact factor: 3.840

2.  Pain relief outcomes using an SCS device capable of delivering combination therapy with advanced waveforms and field shapes.

Authors:  Clark S Metzger; M Blake Hammond; Stephen T Pyles; Edward P Washabaugh; Romanth Waghmarae; Anthony P Berg; James M North; Yu Pei; Roshini Jain
Journal:  Expert Rev Med Devices       Date:  2020-09-21       Impact factor: 3.166

3.  Burst spinal cord stimulation: toward paresthesia-free pain suppression.

Authors:  Dirk De Ridder; Sven Vanneste; Mark Plazier; Elsa van der Loo; Tomas Menovsky
Journal:  Neurosurgery       Date:  2010-05       Impact factor: 4.654

4.  Novel 10-kHz High-frequency Therapy (HF10 Therapy) Is Superior to Traditional Low-frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: The SENZA-RCT Randomized Controlled Trial.

Authors:  Leonardo Kapural; Cong Yu; Matthew W Doust; Bradford E Gliner; Ricardo Vallejo; B Todd Sitzman; Kasra Amirdelfan; Donna M Morgan; Lora L Brown; Thomas L Yearwood; Richard Bundschu; Allen W Burton; Thomas Yang; Ramsin Benyamin; Abram H Burgher
Journal:  Anesthesiology       Date:  2015-10       Impact factor: 7.892

5.  Spinal Cord Stimulation (SCS) Trial Outcomes After Conversion to a Multiple Waveform SCS System.

Authors:  Nameer Haider; Dwight Ligham; Brett Quave; Kirk E Harum; Eduardo A Garcia; Christopher A Gilmore; Nathan Miller; Gregory A Moore; Amarpreet Bains; Kristen Lechleiter; Roshini Jain
Journal:  Neuromodulation       Date:  2018-06-11

6.  Improved Pain Relief With Burst Spinal Cord Stimulation for Two Weeks in Patients Using Tonic Stimulation: Results From a Small Clinical Study.

Authors:  Peter Courtney; Anthony Espinet; Bruce Mitchell; Marc Russo; Andrew Muir; Paul Verrills; Kristina Davis
Journal:  Neuromodulation       Date:  2015-04-16

7.  Effects of Rate on Analgesia in Kilohertz Frequency Spinal Cord Stimulation: Results of the PROCO Randomized Controlled Trial.

Authors:  Simon J Thomson; Moein Tavakkolizadeh; Sarah Love-Jones; Nikunj K Patel; Jianwen Wendy Gu; Amarpreet Bains; Que Doan; Michael Moffitt
Journal:  Neuromodulation       Date:  2017-12-08

8.  Outcomes of a Multicenter, Prospective, Crossover, Randomized Controlled Trial Evaluating Subperception Spinal Cord Stimulation at ≤1.2 kHz in Previously Implanted Subjects.

Authors:  James North; Eric Loudermilk; Albert Lee; Harsh Sachdeva; Demetrios Kaiafas; Edward Washabaugh; Samir Sheth; James Scowcroft; Nagy Mekhail; Benjamin Lampert; Thomas Yearwood; Erik Shaw; Joseph Atallah; Carroll McLeod; John Han; Cong Yu; Mark Sedrak; Rene Lucas; Andrew Trobridge; Joseph Hegarty; Nathan Miller; Lilly Chen; Roshini Jain
Journal:  Neuromodulation       Date:  2019-07-02

9.  Burst SCS Microdosing Is as Efficacious as Standard Burst SCS in Treating Chronic Back and Leg Pain: Results From a Randomized Controlled Trial.

Authors:  Jan Vesper; Philipp Slotty; Stefan Schu; Katja Poeggel-Kraemer; Heike Littges; Pieter Van Looy; Filippo Agnesi; Lalit Venkatesan; Tony Van Havenbergh
Journal:  Neuromodulation       Date:  2018-11-19

10.  Comparison of conventional, burst and high-frequency spinal cord stimulation on pain relief in refractory failed back surgery syndrome patients: study protocol for a prospective randomized double-blinded cross-over trial (MULTIWAVE study).

Authors:  Maxime Billot; Nicolas Naiditch; Claire Brandet; Bertille Lorgeoux; Sandrine Baron; Amine Ounajim; Manuel Roulaud; Aline Roy-Moreau; Géraldine de Montgazon; Elodie Charrier; Lorraine Misbert; Benjamin Maillard; Tanguy Vendeuvre; Philippe Rigoard
Journal:  Trials       Date:  2020-08-03       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.